Acumen Pharmaceuticals, Inc. filed a Form S-3 shelf registration statement with the SEC on October 26, 2026, seeking to offer up to $500,000,000 in securities on a delayed or continuous basis.

Key Highlights

  • Shelf size: The registration covers up to $500,000,000 in aggregate offering price of common stock, preferred stock, debt securities, and warrants, in any combination.
  • Rule 415 offering: Securities may be sold on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933.
  • Stock price at filing: The last reported sale price of common stock on October 23, 2026 was $1.98 per share, according to the filing.
  • Company classifications: The registrant disclosed it is a non-accelerated filer, a smaller reporting company, and an emerging growth company under applicable SEC definitions.
  • Distribution methods: The company disclosed it may sell securities directly to investors, through agents, or through underwriters or dealers, with specific terms to be set out in prospectus supplements.
  • No proceeds disclosed yet: The filing states that net proceeds and pricing will be set forth in each applicable prospectus supplement at the time of any offering.

Acumen Pharmaceuticals Registers Up to $500 Million in Mixed Securities

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), headquartered at 1210-1220 Washington Street, Suite 210, Newton, Massachusetts, filed a Form S-3 registration statement with the Securities and Exchange Commission on October 26, 2026. The filing establishes a shelf registration that would allow the company to offer and sell up to $500,000,000 in securities, including common stock, preferred stock, debt securities, and warrants, in one or more offerings over time. The company's common stock is listed on The Nasdaq Global Select Market under the symbol "ABOS," and the last reported sale price as of October 23, 2026 was $1.98 per share, according to the prospectus.

Under the shelf process, the company disclosed it may sell securities "from time to time" after the registration statement becomes effective. Each offering would be accompanied by a separate prospectus supplement containing specific terms, including pricing and net proceeds. The filing also noted that securities issuable upon conversion, redemption, repurchase, exchange, or exercise of registered securities, including applicable anti-dilution provisions, may be offered under the shelf. The filing states this prospectus "may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement."

The company identified Daniel O'Connell as Chief Executive Officer and Derek Meisner as Chief Legal Officer in the filing. Legal counsel is listed as Ropes and Gray LLP of Boston, Massachusetts. The registrant noted it has elected not to use the extended transition period for complying with new or revised financial accounting standards under Section 7(a)(2)(B) of the Securities Act. The filing directs prospective investors to review risk factors beginning on page 7 of the prospectus and in any applicable prospectus supplement, describing investment in the company's securities as involving "a high degree of risk."

What Was Disclosed

Acumen Pharmaceuticals filed a Form S-3 shelf registration on October 26, 2026, to register up to $500,000,000 in common stock, preferred stock, debt securities, and warrants. Specific offering terms, pricing, and use of proceeds will be detailed in future prospectus supplements.